Design Therapeutics hints at ‘strategic realignment,’ replaces CEO; Karyopharm co-founder leads ATP's Nereid
→ Design Therapeutics chairman Pratik Shah has succeeded João Siffert as CEO while teasing a “strategic realignment” that won’t be revealed until early 2024, according to its Q3 report. Design does elaborate on the status of its cash runway, which is projected to keep the lights on “through 2028” as a result of the changes. Shah has chaired the board since 2017 and is connected to two Laura Shawver biotechs as the ex-chairman of Synthorx — purchased by Sanofi — and the current chairman at ARS Pharmaceuticals, which merged with Shawver-led Silverback Therapeutics last year. Siffert took the top spot at Design in October 2020 after resigning as CEO, head of R&D and CMO at Abeona Therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
